Abstract
Abstract The US Food and Drug Administration's (FDA's) expanded authority to require Risk Evaluation and Mitigation Strategies (REMS) and the increasing importance of comparative effectiveness research and reviews (CERs) under the Affordable Care Act raise a number of public policy issues for prescription drug safety. In addition, the formalization of an interface between the Centers for Medicare and Medicaid Services (CMS) and the FDA to expedite early coverage of drugs, devices and diagnostics raises a number of questions about the extension of CERs into post-marketing drug surveillance requirements. In this commentary, we address the potential applications of CERs and REMS in risk-benefit assessments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Pharmaceutical Health Services Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.